Everhart Financial Group Inc. Has $1.07 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Everhart Financial Group Inc. boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 33.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,209 shares of the pharmaceutical company’s stock after buying an additional 553 shares during the quarter. Everhart Financial Group Inc.’s holdings in Vertex Pharmaceuticals were worth $1,071,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at $31,000. Truvestments Capital LLC increased its position in shares of Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after purchasing an additional 23 shares during the period. Mpwm Advisory Solutions LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $40,000. Midwest Capital Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth $41,000. Finally, Minot DeBlois Advisors LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $44,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Scotiabank lowered their target price on Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Bank of America boosted their target price on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Royal Bank of Canada upped their target price on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a “sector perform” rating in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $460.06 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $462.88 and a 200-day moving average price of $460.24. The company has a market cap of $118.14 billion, a price-to-earnings ratio of -209.12, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $4.76 EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.